ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure
ARCA biopharma, Inc. (ABIO)
US:NASDAQ Investor Relations:
arcabio.com/investors
Company Research
Source: GlobeNewswire
WESTMINSTER, Colo., May 13, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced it recently filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering Gencaro’s (bucindolol hydrochloride) potential treatment effect in preventing atrial fibrillation (AF) in patients with heart failure (HF). The patent application is based on recent novel findings from the GENETIC-AF Phase 2B study of Gencaro, described in “GENETIC-AF: Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined Heart Failure Population,” published in JACC: Heart Failure, a journal of the American College of Cardiology. The new discoveries from the GENETIC-AF study that are covered by the patent application include the key findings that patients who developed AF and HF contemporaneously, and those
Show less
Read more
Impact Snapshot
Event Time:
ABIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABIO alerts
High impacting ARCA biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
ABIO
News
- ARCA biopharma, Inc. (NASDAQ: ABIO) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- Upcoming Stock Splits This Week (September 2 to September 6) – Stay Invested [Yahoo! Finance]Yahoo! Finance
- ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split [Yahoo! Finance]Yahoo! Finance
- ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock SplitGlobeNewswire
- ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka TherapeuticsGlobeNewswire
ABIO
Sec Filings
- 8/30/24 - Form 4
- 8/27/24 - Form SEC
- 8/27/24 - Form SEC
- ABIO's page on the SEC website